BARI 2D

BARI 2D

Bypass Angioplasty Revascularization Investigation 2D. A multicentre, multinational trial comparing the mortality of type-2 diabetics with stable coronary artery disease, managing myocardial ischemia either by immediate revascularisation plus intense medical therapy or by intense medical therapy alone, and management of the diabetes by an insulin-sensitising or by an insulin-providing strategy.

Conclusion
There were similar rates of mortality and major cardiovascular events for prompt revascularisation vs delayed or no revascularisation, and insulin sensitisation vs insulin provision. In high-risk patients selected for CABG, prompt revascularisation reduces major cardiovascular events compared with delayed or no revascularisation, a finding that doesn’t hold for low-risk patients selected for percutaneous coronary intervention.
References in periodicals archive ?
sup][22] Furthermore, the BARI 2D trial showed that elevated baseline plasma Fg level portends poor clinical outcomes with diabetic vasculopathy [sup][20] and provides prognostic influence in unstable coronary disease.
CHICAGO -- Abnormal levels of high-sensitivity cardiac troponin T are present in 40% of type 2 diabetic patients with stable ischemic heart disease, and they do not bode well, according to a secondary analysis of the BARI 2D study.
To address the cardiovascular disease, patients in BARI 2D were randomly assigned to receive intensive medical therapy plus revascularization treatment (such as angioplasty or bypass surgery) or intensive medical therapy alone (with the possibility of revascularization treatment later if their symptoms did not improve).
Diyabetik CDH'da koroner baypas ve ISS etkinligini karsilastiran randomize kontrollu diger iki buyuk calisma FREEDOM ve BARI 2D (18, 19) calismalari da halen devam etmektedir.
The data come from the NIH's Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes study, called BARI 2D, which tracked the health of more than 2,000 patients for five years.
In the post hoc analysis of the BARI 2D data, the investigators compared the rates--between those on rosiglitazone and those not on a TZD--of mortality, MI, stroke, and other outcomes, and composite outcomes among nearly 2,400 patients with type 2 diabetes and coronary artery disease in the study.
ORLANDO - Virtually no patients with type 2 diabetes and documented coronary artery disease and coronary ischemia benefit from immediate coronary revascularization, as long as they receive intensive medical management, based on the outcomes of more than 1,000 patients randomized to the deferred revascularization arm of the BARI 2D trial.
One of the two primary objectives for the BARI 2D study was to determine if a strategy of initial elective coronary revascularization by either bypass surgery or angioplasty combined with aggressive medical therapy results in a lower five-year mortality compared with a strategy of initial aggressive medical therapy alone.
Rosiglitazone therapy n BARI 2D demonstrates rather reassuring efficacy and safety data.
BARI 2D Study Findings to Be Presented at American Diabetes Association Scientific Sessions
Pop-Busui R, Lu J, Brooks MM, et al; the BARI 2D Study Group.
BARI 2D is the first randomized study conducted in patients with mild symptoms and stable ischemic heart disease to show a benefit of CABG in reducing major cardiovascular events, "which were primarily nonfatal myocardial infarction," said cardiologist Robert L.